Skip Navigation

NHLBI In The News

Filter News Mentions

September 15, 2017 : The Guardian

A NHLBI-funded study concluded that five to seven years of hormone replacement therapy does not shorten the lives of post-menopausal women due to increased risk of death from cardiovascular disease or cancer. The findings, published in the journal JAMA, come from a Women’s Health Initiative’s trial, which followed 27,000 women for 18 years.

The New York Times: Taking Hormones for Menopause Doesn’t Raise Early Death Risk

Los Angeles Times: Up to 7 years of hormone therapy is safe for postmenopausal women, new data show

TIME: Why Hormone Replacement Therapy May Be Safer Than You Think

The Seattle Times: Study shows hormone pills don’t shorten older women’s lives

Tech Times: Hormone Replacement Therapy Won’t Cause Early Death, Long-Term Study Finds

Huffington Post: Hormone Therapy Isn’t As Risky As Once Thought, New Study Finds

More coverage

September 13, 2017 : The New England Journal of Medicine

An NHLBI-funded study describes that how the concentration of mucins, the proteins that thicken mucus, is high in chronic bronchitis and directly associated with the severity of the condition. The findings, published in The New England Journal of Medicine, are “an important step forward for COPD research. Understanding how characteristics of mucus relate to disease severity and symptoms may help us develop new COPD therapies as well as new ways to predict who will benefit most from different treatments,” said James P. Kiley, PhD, director of the NHLBI Division of Lung Diseases.

Today Topics: New insights on chronic bronchitis could lead to first diagnostic test and better treatments

Newswise: Chronic bronchitis new insights could lead to first diagnostic test and better treatments

Med India: New Insights Into Chronic Bronchitis Can Lead to Better Treatments

September 4, 2017 : Annals of Internal Medicine

A study published in the Annals of Internal Medicine showed that, while intensive systolic blood pressure control increased the risk for chronic kidney disease events, it was outweighed by the potential cardiovascular benefits. The study is a subgroup analysis of the Systolic Blood Pressure Intervention Trial (SPRINT).

2 Minute Medicine: Cardiovascular benefits of intensive systolic blood pressure control may outweigh risks of chronic kidney disease events

September 4, 2017 : Nature Genetics

In a large analysis of genetic data, a team of researchers partly funded by NHLBI found that heart disease and Type 2 diabetes, the two diseases that are the leading cause of global morbidity and mortality, are linked by the same genes. The study published in Nature Genetics offers potential for drugs that could address both conditions.

Business Standard: One pill to ward off diabetes, heart disease could soon be reality

Global News: Diabetes and heart disease risk are linked by the same genes, scientists say

AJMC: Study Finds Genetic Links Between Diabetes, Heart Disease; Reveals Potential Drug Targets

Medical News Today: Type 2 diabetes shares risk genes with heart disease

August 30, 2017 : Nature

Researchers partly funded by NHLBI have used a modified version of CRISPR, the gene editing technique, to identify genetic regulatory elements (enhancers) involved in autoimmune diseases. According to the researchers, the findings, published in Nature, start to “unlock the fundamental circuitry of immune cell regulation, which will dramatically increase our understanding of disease.”

GEN News: CRISPR Genome Scan Reveals Key Immune System Regulators

EurekAlert! Blunting CRISPR's 'scissors' gives new insight into autoimmune disorders

MeicalXpress: Blunting CRISPR's 'scissors' gives new insight into autoimmune disorders

August 27, 2017 : The New York Times

Anti-inflammatory drugs could cut the risk of heart attacks and strokes, according to a study published on The New England Journal of Medicine. The researchers reported a 15-percent reduction in risk of a cardiovascular event, including fatal and non-fatal heart attacks and strokes, for clinical trial participants who received 150 or 300 mg of an anti-inflammatory drug, compared with those on the placebo.

Washington Post: Major drug study opens up vast new opportunities in combating heart disease

BBC News: Anti-inflammatory drug 'cuts heart attack risk'

MedPage Today: ESC: At Long Last, Inflammatory Hypothesis Confirmed in CVD by CANTOS

Forbes: Inflammation: Is It the New Cholesterol?

ScienceDaily: Inflammatory Hypothesis Confirmed: Reducing Inflammation Without Lowering Cholesterol Cuts Risk of Cardiovascular Events

August 24, 2017 : University of Utah

NHLBI-funded studies published by The New England Journal of Medicine provide additional support for intensive blood pressure control in patients with high risk of cardiovascular disease. The study about the cost-effectiveness of this approach “is important not just because it shows that the long-term benefits of intensive blood pressure treatment outweigh considerations about costs and side effects, but because of its population-wide implications,” said co-author Lawrence Fine M.D., Dr.P.H., Chief of the Branch of Clinical Applications and Prevention at NHLBI. The authors of the study on patient-reported outcomes found that intensive blood pressure treatment appeared to be safe and well tolerated.

The New England Journal of Medicine: Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control

The New England Journal of Medicine: Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes

WebMD: More Support for Tight Blood Pressure Control

DoctorsLounge: Intensive BP Treatment Appears Safe, Well Tolerated

MedpageToday: SPRINT's Intense BP Targeting Likely Cost-Effective

More coverage

August 22, 2017 : JAMA

A medical strategy involving the use of natriuretic peptide as a biomarker does not appear to benefit patients with heart failure, according to researchers.  Their study, called GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment (GUIDE-IT), compared the biomarker-guided strategy to usual care among a group of high-risk heart failure patients and found no difference between the two approaches in terms of hospitalization and heart-related death.  Although the GUIDE-IT study itself was halted in 2016 because it showed no benefit, the researchers have now published the details of their study in the Journal of the American Medical Association. NHLBI funded the study. 

Duke Clinical Research Institute: Biomarker-guided therapy in heart failure does not add to usual care, say researchers

MedPage Today: NT-proBNP Tx Disappoints for HF Drug Titration

Healio: GUIDE-IT: NT-proBNP-guided strategy fails to improve outcomes in HFrEF

Medical Xpress: NT-ProBNP-guided treatment no benefit in high-risk HFrEF

August 9, 2017 : JAMA Cardiology

There has been a substantial reduction in racial differences in survival after in-hospital cardiac arrest, with a greater improvement in survival among black patients compared with white patients, according to a study published by JAMA Cardiology.

Lincoln Journal Star: Racial Gap Narrows for Survival of Hospitalized Cardiac Arrest Patients

Physician's Briefing: Smaller Racial Gap in Survival After In-Hospital Cardiac Arrest

MedPage Today: Racial Gap Closes for In-Hospital Cardiac Arrest Survival

More coverage

August 8, 2017 : The Huffington Post

Middle aged people with risk factors for heart attacks and stroke, including diabetes, high blood pressure and smoking, have a greater chance of suffering from dementia later in life, according to a study, partly funded by NHLBI, published in JAMA Neurology.

The Huffington Post: Heart Disease Risk In Middle Age Tied To Dementia Later

WebMD: 'Heart Harm' In Middle Age Can Lead To Dementia

Drug Discovery and Development: Midlife Heart Health Linked to Risk of Dementia

Medscape: Prehypertension in Midlife Ups Later Dementia Risk

Medpage Today: Midlife Vascular Risk Factors Linked to Dementia

Business Standard: Diabetes, high BP in midlife may up dementia risk later

More coverage

Page 3 of 91


Subscribe to NHLBI In The News